We are live on ! Find out more

Penumbra

PEN

Market cap $12.6B

318.95 USD

-3.02

0.94%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

319.01

+0.06

0.02%

1 day

-0.94%

5 days

-1.52%

1 month

0.19%

3 months

-0.28%

6 months

-2.31%

Year to date

3.08%

1 year

37.75%

5 years

14.1%

10 years

383.62%

About: Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.

Employees: 4,700

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 44.4%

Neutral 55.6%

Negative 0%

Penumbra, Inc. Reports Third Quarter 2026 Financial Results

ALAMEDA, Calif., Oct. 29, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026.

Penumbra, Inc. Reports Third Quarter 2026 Financial Results

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective ALAMEDA, Calif., Oct. 20, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company's Lightning™ computer assisted vacuum thrombectomy (CAVT™) technology.

Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

Wearable-derived data provide new insights into how clinical outcomes for patients treated with CAVT and anticoagulation, and anticoagulation alone translate to patients' everyday recovery ALAMEDA, Calif., Oct. 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced results from a subset analysis of the landmark STORM-PE randomized controlled trial (RCT), the first trial to demonstrate a significant correlation between real-world, daily step-based activity as captured on a consumer wearable device and patient performance in the clinical 6-minute walk test.

New STORM-PE Data Demonstrate Correlation Between Clinical Assessments and Real-world Functional Recovery Captured Through Wearable Technology in Patients with Pulmonary Embolism

Zacks Investment Research

IART vs. PEN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?

IART vs. PEN: Which Stock Is the Better Value Option?

Zacks Investment Research

IART or PEN: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?

IART or PEN: Which Is the Better Value Stock Right Now?

Zacks Investment Research

Reasons to Retain Penumbra Stock in Your Portfolio for Now

PEN's portfolio expansion and international growth support momentum, while rising costs, FX exposure and margin pressure remain key risks.

Reasons to Retain Penumbra Stock in Your Portfolio for Now

Zacks Investment Research

TFX vs. PEN: Which Stock Is the Better Value Option?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks is more attractive to value investors?

TFX vs. PEN: Which Stock Is the Better Value Option?

Zacks Investment Research

TFX or PEN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two companies is the best option for those looking for undervalued stocks?

TFX or PEN: Which Is the Better Value Stock Right Now?

Zacks Investment Research

TFX vs. PEN: Which Stock Is the Better Value Option?

Investors interested in Medical - Instruments stocks are likely familiar with Teleflex (TFX) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now?

TFX vs. PEN: Which Stock Is the Better Value Option?

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.

Penumbra, Inc. Reports Second Quarter 2026 Financial Results

See News Rankings

Price charts implemented using Lightweight Charts™